**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 57-year-old man developed haemodynamic instability and supraventricular tachycardia during fibrinolysis with alteplase for pulmonary embolism. Additionally, he showed lack of efficacy to multiple drugs \[*route and duration of treatment to reaction onset not stated*\].

The man, who had diabetes, morbid obesity and hypertension was diagnosed with COVID-19 infection. His home medications included aspirin, valsartan, simvastatin, amlodipine and metformin. Subsequently, due to severe hypoxia he was transferred to the ICU. During admission, he was clinically deteriorated and he required orotracheal intubation. He had hypoxemic respiratory failure and signs of acute kidney injury. Immediately, mechanical thromboprophylaxis was started. CT scan was suggestive of viral pneumonia. For treatment of Covid 19, he started receiving azithromycin, ceftaroline fosamil \[ceftaroline\] and hydroxychloroquine off labelly. On day 2 of admission, unfractionated heparin was administered as an anticoagulant due to altered D-dimer. On day 5 of admission, he developed oxygen desaturation, bradycardia and severe hypotension. He did not stabilise despite treatment with atropine, epinephrine \[adrenaline\] and norepinephrine \[noradrenaline\]. Thereafter, following several investigations, he was additionally diagnosed with pulmonary embolism. Therefore, he underwent catheter guided fibrinolysis at right pulmonary artery with alteplase \[Actilyse\] 10mg injection, followed by thrombectomy in the right pulmonary artery. A large amount of thrombus was removed from the left pulmonary artery. For the remaining thrombus, he was given an injection of alteplase 18mg followed by thrombectomy. Subsequently, he improved, but during subsequent thrombectomy, he developed supraventricular tachycardia which did not respond to adenosine 12mg along with haemodynamic impairment. This led to interruption of thrombectomy. For haemodynamic stabilisation, removal of the trans valvar vascular sheath was required and at last inferior vena cava was deployed. He was then taken back to the ICU and thrombolytic treatment was maintained with low dose of alteplase (50mg in 1 hour). During the subsequent month, he showed ventilatory and haemodynamic improvement, without requiring vasopressors. After 10 days of the intervention, he was successfully extubated. Later, he was discharged with oral anticoagulants and was asked for a clinical follow up.
